Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Armando Martínez, general manager at Beckman Coulter Mexico, explains the company’s unique business model Coulter, the strong added-value of its broad and innovative healthcare solutions, and how they help improve…
Abelardo Meneses García, General Director at the National Cancer Institute of Mexico (INCan), explains the evolution of cancer’s footprint in Mexico and showcases how the institute has been investing in…
José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value…
Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s…
GM Gerardo Torres-Septién explains how Grupo Rasch has managed to grow during the last two years and showcases the added value of its solutions to help the pharmaceutical industry enhance…
Juan Francisco Hernández, general manager of Latin America at Wockhardt, showcases the added value of the company to the entire region based on quality, safety and cost-effective medicines targeting diabetes,…
María Teresa Lopez, managing director at Zimmer Biomet Mexico, discusses the medtech company’s strong commitment to Mexico as well as the high added value of its broad and innovative health…
Alberto Wicker, CEO at Signufarma, explains how patient compliance programs can enhance the national healthcare system through reducing the cost of treatment as well as improving patients’ quality of life…
Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients…
Patricia López, general manager at seca Mexico, showcases the added value of seca’s product portfolio and explains that interconnectivity should be medical devices’ path of development; generating benefits for patients,…
Patrick Troop, CEO at Pharma Tycsa, explains the company’s unique business approach in Mexico developing “clinical pharmacies” model to address chronic diseases treatment in the points of care and the…
Victor Manuel Fernández Navarro, CEO at Vicma, explains how strategically important is to have a healthy business model in the distribution industry through sustainable collection period, attractive profit margins and…
See our Cookie Privacy Policy Here